| Code |
OSS00125W |
| ID Tag |
Rb775-140209-WS |
| Ordering info |
Order online using the shopping cart ("Add to Cooler"), by email to
sales@osenses.com
or fax to 61-8-827 0 8586 and pay via PayPal by
MasterCard or Visa. You can also provide us with your Purchase Order Number (PON) and pay by check or wire transfer. Alternatively contact our distributors.
This item is in our stock. The handling & shipping cost is $48 USD and the expected delivery time is within 5 business days worldwide.
 |
| Unit size |
100 µl |
| Immunogen |
A synthetic peptide from c-terminal region of human Synphilin-1 (Synphilin 1, alpha synuclein interacting protein) conjugated to an immunogenic carrier protein was used as the antigen. The antigen shares 83% identity with mouse sequence. |
| Conjugate |
Unconjugated antibody |
| Accession |
SNCAIP_HUMAN
SNCAIP_MOUSE |
| Also known as |
Alpha-synuclein-interacting protein, SNCAIP |
| Background |
Tissue specificity: Widely expressed, with highest levels in brain, heart and placenta.
Defects in SNCAIP are a cause of Parkinson disease (PD). PD is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.
Constructs encoding portions of SNCA and SNCAIP co-transfected in mammalian cells promote cytosolic inclusions resembling the Lewy bodies of Parkinson disease. Coexpression of SNCA, SNCAIP, and PARK2 result in the formation of Lewy body-like ubiquitin-positive cytosolic inclusions. Familial mutations in PARK2 disrupt the ubiquitination of SNCAIP and the formation of the ubiquitin-positive inclusions. These results provide a molecular basis for the ubiquitination of Lewy body-associated proteins and link PARK2 and SNCA in a common pathogenic mechanism through their interaction with SNCAIP. |
| Host |
NZ white rabbit |
| Purity |
Whole serum |
| Clonality |
Polyclonal |
| Isotype |
Polyclonal, whole serum |
| Applications |
IHC, WB. A dilution of 1: 300 to 1: 2000 is recommended. The optimal dilution should be determined by the end user. Not yet tested in other applications. |
| Specificity |
Specific for Synphilin-1. |
| Spcs X-react. |
Human. Other species not yet tested. |
| Format |
Lyophilised |
| Reconstitution |
Reconstitute in 100 µl of sterile water. Centrifuge to remove any insoluble material. |
| Storage |
Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles. |
| Expiry Date |
12 months after reconstitution |
| Transportation |
This item will be shipped to you at ambient temperature in a lyophilised form. |
| References |
1. Ito T, et al. J. Biol. Chem. 278:29106-29114(2003)
2. Engelender S, et al. Mamm. Genome 11:763-766(2000)
3. Chung K.K.K, et al. Nat. Med. 7:1144-1150(2001)
4. Nagano Y, et al. J. Biol. Chem. 278:51504-51514(2003)
5. Imami K, et al. Anal. Sci. 24:161-166(2008) |
| Limitation |
For research use only |
Primary Antibodies 
